KRL 104Alternative Names: KRL-104
Latest Information Update: 17 May 2016
At a glance
- Originator Krele Pharmaceuticals
- Developer Tonix Pharmaceuticals Inc
- Class Anxiolytics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Generalised anxiety disorder
Most Recent Events
- 26 Mar 2009 Clinical trials in Generalised anxiety disorder in USA (unspecified route)